ccfDNA Quantification |
ccfDNA (ng/mL) |
qPCR |
Mouliére et al., 2014Moulière F, El Messaoudi S, Pang D, Dritschilo A, Thierry AR. Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol Oncol. 2014;8(5):927-41.; Kondratov et al., 2014Kondratov AG, Nekrasov KA, Lototska LV, Panasenko GV, Stoliar LA, Lapska YV, et al. Comparative analysis of epigenetic markers in plasma and tissue of patients with colorectal cancer. Biopolym Cell. 2014;30(2):129-34.. |
Fluorimetry (SybrGold) |
Czeiger et al., 2011Czeiger D, Shaked G, Eini H, Vered I, Belochitski O, Avriel A, et al. Measurement of circulating cell-free dna levels by a new simple fluorescent test in patients with primary colorectal cancer. Am J Clin Pathol. 2011;135(2):264-70.
|
UV spectrophotometry |
Schwarzenbach et al., 2008Schwarzenbach H, Stoehlmacher J, Pantel K, Goekkurt E. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci. 2008;1137:190-6.
|
DNA DipStick Kit |
Frattini et al., 2008Frattini M, Gallino G, Signoroni S, Balestra D, Lusa L, Battaglia L, et al. Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett. 2008; 236(2):170-81., Frattini et al., 2006 |
Fluorimetry (Quant-iT™ PicoGreen®dsDNA Kit) |
Heitzer et al., 2013Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer. 2013;133(2):346-57.
|
ccfDNA (alleles/mL) |
qPCR |
Spindler et al., 2015Spindler KLG, Pallisgaard N, Andersen RF, Brandslund I, Jakobsen A. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. PLoS One. 2015;10(4 art.e0108247):1-14.
|
MetDNA |
mGATA5
|
Qiagen Epitect Plus DNA bisulfite kit + MSP |
Zhang et al., 2015Zhang X, Song YF, Lu HN, Wang DP, Zhang XS, Huang SL, et al. Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas. World J Gastroenterol. 2015;21(9):262937.
|
mSFRP2
|
Qiagen Epitect Plus DNA bisulfite kit + MSP |
Zhang et al., 2015Zhang X, Song YF, Lu HN, Wang DP, Zhang XS, Huang SL, et al. Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas. World J Gastroenterol. 2015;21(9):262937.
|
mITGA4
|
Qiagen Epitect Plus DNA bisulfite kit + MSP |
Zhang et al., 2015Zhang X, Song YF, Lu HN, Wang DP, Zhang XS, Huang SL, et al. Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas. World J Gastroenterol. 2015;21(9):262937.
|
mFOXE1
|
EpiTect Bisulphite Kit + MSP |
Melotte et al., 2015Melotte V, Yi JM, Lentjes MH, Smits KM, Van Neste L, Niessen HE, et al. Spectrin repeat containing nuclear envelope 1 and forkhead box protein e1 are promising markers for the detection of colorectal cancer in blood. Cancer Prev Res. 2015;8(2):15764.
|
mSYNE1
|
EpiTect Bisulphite Kit + MSP |
Melotte et al., 2015Melotte V, Yi JM, Lentjes MH, Smits KM, Van Neste L, Niessen HE, et al. Spectrin repeat containing nuclear envelope 1 and forkhead box protein e1 are promising markers for the detection of colorectal cancer in blood. Cancer Prev Res. 2015;8(2):15764.
|
mPPP1R3C
|
Zymo EZ DNA Methylation Kit + MSP |
Takane et al., 2014Takane K, Midorikawa Y, Yagi K, Sakai A, Aburatani H, Takayama T, et al. Aberrant promoter methylation of PPP1R3C and EFHD1 in plasma of colorectal cancer patients. Cancer Med. 2014;3(5):1235-45.
|
mEFHD1
|
Zymo EZ DNA Methylation Kit + MSP |
Takane et al., 2014Takane K, Midorikawa Y, Yagi K, Sakai A, Aburatani H, Takayama T, et al. Aberrant promoter methylation of PPP1R3C and EFHD1 in plasma of colorectal cancer patients. Cancer Med. 2014;3(5):1235-45.
|
mSEPT9
|
Epi proColon Assay |
Church et al., 2014Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63(2):317-25.
|
|
Bisulfite conversion + Real time PCR |
deVos et al., 2009 |
mBCAT1
|
EpiTect Fast Bisulfite Conversion kit + MSP |
Pedersen et al., 2015Pedersen SK, Baker RT, McEvoy A, Murray DH, Thomas M, Molloy PL, et al. A two-gene blood test for methylated DNA sensitive for colorectal cancer. PLoS One. 2015;10(4 art. e0125041):1-14.
|
mIKZF1
|
EpiTect Fast Bisulfite Conversion kit + MSP |
Pedersen et al., 2015Pedersen SK, Baker RT, McEvoy A, Murray DH, Thomas M, Molloy PL, et al. A two-gene blood test for methylated DNA sensitive for colorectal cancer. PLoS One. 2015;10(4 art. e0125041):1-14.
|
ccfDNA Integrity |
ALU115 |
qPCR |
Hao et al., 2014Hao TB, Shi W, Shen XJ, Qi J, Wu XH, Wu Y, et al. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer. 2014;111(8):1482-9.
|
ALU247/ALU115 |
qPCR |
Hao et al., 2014Hao TB, Shi W, Shen XJ, Qi J, Wu XH, Wu Y, et al. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer. 2014;111(8):1482-9.
|
qPCR |
Yoruker et al., 2015Yörüker EE, Özgür E, Keskin M, Dalay N, Holdenrieder S, Gezer U. Assessment of circulating serum DNA integrity in colorectal cancer patients. Anticancer Res. 2015;35(4):2435-40.
|
ACTB384 / ACTB106 |
qPCR |
Yoruker et al., 2015Yörüker EE, Özgür E, Keskin M, Dalay N, Holdenrieder S, Gezer U. Assessment of circulating serum DNA integrity in colorectal cancer patients. Anticancer Res. 2015;35(4):2435-40.
|